

Supplementary Table 1. Univariate and multivariate analyses for prechemotherapy PFS

Variable	Univariate			Multivariate		
	HR	95% CI	p value	HR	95% CI	p value
Age, yr						
< 65	1.00					
≥ 65	1.06	0.87–1.28	0.589		NS	
Sex						
Female	1.00					
Male	1.18	0.97–1.43	0.091		NS	
Detecting metastasis						
Recurrence	1.00			1.00		
Initial diagnosis	1.49	1.21–1.84	< 0.001	1.36	1.10–1.69	0.005
Histological type						
Differentiated	1.00			1.00		
Undifferentiated	1.28	1.05–1.55	0.017	1.33	1.09–1.63	0.005
Peritoneal carcinomatosis						
No	1.00					
Yes	1.20	1.00–1.45	0.055		NS	
No. of metastatic organs						
1	1.00			1.00		
≥ 2	1.58	1.30–1.92	< 0.001	1.48	1.21–1.81	< 0.001
First line chemotherapy						
Cisplatin based	1.00					
Non-cisplatin based	1.02	0.81–1.29	0.850		NS	
Prechemotherapy NLR						
< 3.0	1.00			1.00		
≥ 3.0	1.37	1.13–1.66	0.002	1.42	1.17–1.73	< 0.001
Prechemotherapy mGPS						
Low	1.00					
High	1.21	0.94–1.56	0.131		NS	

PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; NS, not significant; NLR, neutrophil-to-lymphocyte ratio; mGPS, modified Glasgow prognostic score.